CA3223210A1 - Novel ergolines and methods of treating mood disorders - Google Patents

Novel ergolines and methods of treating mood disorders Download PDF

Info

Publication number
CA3223210A1
CA3223210A1 CA3223210A CA3223210A CA3223210A1 CA 3223210 A1 CA3223210 A1 CA 3223210A1 CA 3223210 A CA3223210 A CA 3223210A CA 3223210 A CA3223210 A CA 3223210A CA 3223210 A1 CA3223210 A1 CA 3223210A1
Authority
CA
Canada
Prior art keywords
disorder
alkyl
compound
group
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3223210A
Other languages
English (en)
French (fr)
Inventor
Andrew Carry KRUEGEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilgamesh Pharmaceuticals Inc
Original Assignee
Gilgamesh Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilgamesh Pharmaceuticals Inc filed Critical Gilgamesh Pharmaceuticals Inc
Publication of CA3223210A1 publication Critical patent/CA3223210A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C07D457/08—Lysergic acid amides in which the amide nitrogen is a member of a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3223210A 2021-04-23 2022-04-25 Novel ergolines and methods of treating mood disorders Pending CA3223210A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163179053P 2021-04-23 2021-04-23
US63/179,053 2021-04-23
US202263308376P 2022-02-09 2022-02-09
US63/308,376 2022-02-09
PCT/US2022/026186 WO2022226408A1 (en) 2021-04-23 2022-04-25 Novel ergolines and methods of treating mood disorders

Publications (1)

Publication Number Publication Date
CA3223210A1 true CA3223210A1 (en) 2022-12-27

Family

ID=81648213

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3223210A Pending CA3223210A1 (en) 2021-04-23 2022-04-25 Novel ergolines and methods of treating mood disorders

Country Status (10)

Country Link
US (1) US20240368151A1 (https=)
EP (1) EP4326718A1 (https=)
JP (1) JP2024516174A (https=)
KR (1) KR20240019091A (https=)
AU (1) AU2022262659A1 (https=)
BR (1) BR112023021970A2 (https=)
CA (1) CA3223210A1 (https=)
IL (1) IL307880A (https=)
MX (1) MX2023012447A (https=)
WO (1) WO2022226408A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230116703A1 (en) * 2021-04-23 2023-04-13 Gilgamesh Pharmaceuticals, Inc. Novel ergolines and methods of treating mood disorders
CN117355302A (zh) 2021-04-30 2024-01-05 思维医学股份有限公司 Lsd盐晶体形式
JP2024529727A (ja) 2021-08-19 2024-08-08 マインド メディシン， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤
JP2025525375A (ja) * 2022-06-20 2025-08-05 マインド メディシン， インコーポレイテッド 修飾ｌｓｄ様作用を有するリゼルグ酸誘導体
EP4630418B1 (en) * 2022-12-31 2026-03-18 Ceruvia Lifesciences LLC Salts of 2-bromolysergic acid diethylamide
EP4704846A2 (en) * 2023-05-04 2026-03-11 Gilgamesh Pharmaceuticals, Inc. Novel ergolines and methods of treating mood disorders
WO2025194238A1 (en) * 2024-03-22 2025-09-25 Blife Therapeutics Inc. 2-bromo-lsd salts and polymorphs
WO2025235800A1 (en) 2024-05-08 2025-11-13 Cy Biopharma Ag Ergoline derivatives and uses thereof
WO2025235784A2 (en) * 2024-05-08 2025-11-13 Cy Biopharma Ag Ergoline derivatives and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2438259A (en) * 1948-03-23 D-lysergic acid diethyl amide
CN1087725C (zh) * 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
EP4219498A1 (en) * 2019-03-07 2023-08-02 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
US20230295106A1 (en) * 2019-10-14 2023-09-21 The Regents Of The University Of California Ergoline-like compounds for promoting neural plasticity
EP4178956A2 (en) * 2020-07-07 2023-05-17 COMPASS Pathfinder Limited Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof

Also Published As

Publication number Publication date
IL307880A (en) 2023-12-01
AU2022262659A1 (en) 2023-10-19
US20240368151A1 (en) 2024-11-07
EP4326718A1 (en) 2024-02-28
WO2022226408A1 (en) 2022-10-27
JP2024516174A (ja) 2024-04-12
KR20240019091A (ko) 2024-02-14
BR112023021970A2 (pt) 2023-12-26
MX2023012447A (es) 2023-10-31

Similar Documents

Publication Publication Date Title
CA3223210A1 (en) Novel ergolines and methods of treating mood disorders
EP4608829A2 (en) Novel ergolines and methods of treating mood disorders
JP4932065B2 (ja) βセクレターゼ阻害剤としてのラクタム
CN109496213B (zh) 螺环化合物及其制备和使用方法
JP7237010B2 (ja) Ｈｄａｃ６選択的阻害剤およびその製造方法と使用
EP4704846A2 (en) Novel ergolines and methods of treating mood disorders
AU2022234444A1 (en) Phenalkylamines and methods of making and using the same
AU2009352490B2 (en) 1, 2-dihydro-2-oxoquinoline compounds as 5-HT 4 receptor ligands
US9216977B2 (en) Antofine and cryptopleurine derivatives as anticancer agents
JP2008542375A (ja) Ｏｒｌ−１受容体モジュレーターとして有用な新規３−スピロ環式インドリル誘導体
US10017507B2 (en) Diaza-benzofluoranthrene compounds
CN105985333A (zh) 二氮杂-苯并荧蒽类化合物
EP4466266B1 (en) Fused heterocycles as 5-ht2a receptor agonists
CN121002004A (zh) 取代的噻吩稠合衍生物、包含其的组合物及其作为药物的用途
JP2010502760A (ja) うつ病の治療用の３−アザビシクロ［４．１．０］ヘプタン誘導体
TWI858711B (zh) Ｒ拮抗劑及其用途
WO2016075457A1 (en) Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders
CN120787225A (zh) 新型麦角林类和治疗心境障碍的方法
CN117677618A (zh) 新颖的麦角灵类和治疗心境障碍的方法
WO2024059090A1 (en) Phenalkylamines and methods of making and using the same
WO2025059373A1 (en) Novel phenalkylamines and their use in the treatment of psychiatric disorders
WO2022215754A1 (ja) 二環性ピリジン誘導体
CN121816345A (zh) 5-ht2a受体调节剂及其使用方法
CN121712775A (zh) 5-ht2a受体调节剂及其使用方法
HK40004417A (en) Spirocycle compounds and methods of making and using same

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250324

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808